High-potency Fluorenol analogs: –10.7 kcal/mol. Molecular Docking of Selective analogs Dopamine D1A

High-potency Fluorenol analogs: Achieving Binding Energies Exceeding –10.7 kcal/mol. Molecular Docking of Selective analogs Dopamine D1A Receptor. Keywords: analogs, Dopamine D1A Receptor Agonist, Dopamine D2A Receptor, Molecular Docking & Affinity Optimization, Asymmetric Heterocyclic Scaffold, Structure-Activity Relationship (SAR), High-Resolution Binding Energy (–10 kcal/mol), Cyclopentane-fused Imidazoline, Bi-Three-Quadru-Pentadentate Hydrogen Bonding (Fork-like Docking), Conformational Rigidity, Pi-Pi Stacking & Lipophilic Resonance, Molecular Docking Fluorenol is a selective nootropic agent with a mild dopaminergic effect. It acts as an agonist at the dopamine D1A receptor, forming a hydrogen bond with the Asp103 residue via its hydroxyl group. This interaction occurs without an ionic component (Figure 1), resulting in a calculated binding energy of –8.1 kcal/mol. This, combined with the specific hydrogen bonding of the alcohol, results in the mild pharmacological effect characteristic of this group. Fluorenol shows no significant binding affinity for the D2A receptor, which is a positive characteristic of the fluorene core. However, this agonism, coupled with its relatively low binding energy, requires significant dosages that approach the safety threshold for fused lipophilic aromatic derivatives. Therefore, the search for tautomers, derivatives, and new scaffolds with similar characteristics is a standard tactic. Increasing the binding affinity promotes a more...